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Genome-wide scan for genes involved in bipolar affective disorder in 70 European 
families ascertained through a bipolar type I early onset proband : supportive evidence 
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Summary 
Preliminary studies suggested that age at onset (AAO) may help to define homogeneous 
bipolar affective disorder (BPAD) subtypes. This candidate symptom approach might be 
useful to identify vulnerability genes. Thus, the probability of detecting major disease-causing 
genes might be increased by focusing on families with early-onset BPAD type I probands. 
This study was conducted as part of the European Collaborative Study of Early Onset BPAD 
(France, Germany, Ireland, Scotland, Switzerland, England, Slovenia). We performed a 
genome-wide search with 384 microsatellite markers using non parametric linkage analysis in 
87 sib-pairs ascertained through an early-onset BPAD type I proband (age at onset of 21 years 
or below). Non parametric multi-point analysis suggested eight regions of linkage with p-
values <0.01 (2p21, 2q14.3, 3p14, 5q33, 7q36, 10q23, 16q23 and 20p12). The 3p14 region  
showed the most significant linkage (genome-wide p-value estimated over 10.000 simulated 
replicates of 0.015 [0.01-0.02]). After genome-wide search analysis, we performed additional 
linkage analyses with increase marker density using markers in four regions suggestive for 
linkage and having an information contents lower than 75% (3p14, 10q23, 16q23 and 20p12). 
For these regions, the information content improved by about 10%. In chromosome 3, the non 
parametric linkage score increased from 3.51 to 3.83. This study is the first to use early onset 
bipolar type I probands in an attempt to increase sample homogeneity. These preliminary 
findings require confirmation in independent panels of families. 
 
     
H
AL author m
anuscript    inserm
-00132874, version 1
 4  
Introduction 
Bipolar affective disorder (BPAD) is a chronic psychiatric disorder with a lifetime cumulative 
risk of around one percent, affecting males and females equally (1). Family, twin and to a less 
extent adoption studies strongly support a genetic component of BPAD, buts its mode of 
inheritance remains unclear (1-3). Genome-wide searches have detected numerous 
chromosomal regions possibly linked to BPAD, leading to conflicting results. A recent meta-
analysis of 18 BPAD genome scan data-sets (4) suggested that no chromosomal region 
achieved genome-wide statistical significance according to several simulation-based criteria. 
However, the most significant p values (<0.01) were observed for chromosomes 9p22.3-21.1, 
10q11.21-22.1 and 14q24.1-32.12. The discrepancies between studies may be explained by 
differences in study design (including sample size, type of family structure, mode of 
ascertainment, phenotypic definitions and statistical methods used) and potential false-
positive results. These conflicting results may also be due to the lack of a consensus definition 
for the affected phenotype and the possible clinical heterogeneity of BPAD (5).  
Several studies have suggested that early-onset BPAD is a clinically and genetically 
homogeneous subtype of BPAD with greater heritability than late-onset BPAD. Clinical 
studies have demonstrated that early-onset BPAD is a more severe form of the disease, 
characterized by frequent psychotic features, more mixed episodes, greater psychiatric co-
morbidity (with panic disorder and alcohol/drug abuse or dependence) and poorer response to 
prophylactic lithium (6-8). Familial aggregation is stronger in relatives of early-onset (15% to 
30%) than of late-onset (3%) BPAD probands (6-10). Finally, several studies have suggested 
the existence of an intra-familial correlation for age at onset (AAO) among bipolar siblings 
(11, 12). A recent segregation analysis showed that BPAD is transmitted differently in early- 
and late-onset BPAD families (10). Several association studies investigating early-onset 
BPAD subgroups suggested the implication of candidate genes such as those encoding 
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glycogen synthase kinase 3-beta (OMIM number 605004) (13) and the dopamine receptor D3 
(OMIM number 126451) (14). Finally, polymorphisms in the serotonin transporter (SLC6A4 
- OMIM number 182138) and apolipoprotein E (OMIM number 107741) genes seem to 
influence BPAD age at onset (15-17).  
Thus, we hypothesized that focusing on families ascertained through an early-onset type I 
BPAD proband might reduce the heterogeneity of the BPAD phenotype, thus increasing the 
probability of detecting risk loci by linkage analysis. Such a “symptom candidate approach” 
(5) using age at onset has been already used in other complex diseases such as breast cancer 
or Alzheimer disease and has been useful in identifying susceptibility genes (18, 19). We 
recruited a large sample of sib-pairs including one sibling with early-onset type I BPAD as 
part of the European Collaborative Study of Early Onset BPAD (France, Germany, Ireland, 
Scotland, Switzerland, England and Slovenia). The aim of the study is to find genetic factors 
involved in BPAD in an homogeneous sample ascertained through an early onset type I 
BPAD proband. This is the first genome-wide search performed using both bipolar I disorder  
and AAO as inclusion criteria for ascertainment.  
 
Materials and Methods 
 
Subjects 
Families were recruited within the European Collaborative Study of Early-Onset BPAD and 
were eligible for inclusion only if the proband met the DSM-IV criteria (20) for BPAD type I 
with an AAO of 21 years or below. BPAD type I is defined by the presence of manic episodes 
with or without depressive episodes. BPAD type II is defined by the presence of hypomanic 
episodes with depressive episodes (20). The age at onset threshold was chosen according to a 
previous admixture analysis (21) that has been replicated (22) in two large independent 
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samples of BPAD I patients. These studies identified three AAO subgroups: early (AAO < 21 
years old), intermediate and late onset (AAO > 37 years old). Here, AAO was defined for all 
centers as the age of the first thymic episode (depressive, manic or hypomanic) determined by 
reviewing medical case notes and information from semi-structured interviews. Affected 
sibling was diagnosed with BPAD (type I or II) or schizo-affective disorder with no specific 
requirements regarding AAO, or with major depressive episode (MDE, single or recurrent) 
with an AAO of 21 years or below. In this study, patients suffering from recurrent major 
depressive episodes with age at onset below 21 years old were considered as affected, because 
it was postulated that they belong to the bipolar spectrum disorder as defined by Ghaemi et al. 
(23). In addition, siblings of BPAD I early onset probands suffering from only one major 
depressive episode beginning before the age of 21 years old are known to be at high risk of 
progression to bipolar disorder (24, 25) .  
Each participant (proband, sibling and parents) was interviewed by a trained psychiatrist 
using one of the following instruments: Diagnostic Interview for Genetic Studies (DIGS) 
(26), Composite International Diagnostic Interview (CIDI) (27), Structured Clinical Interview 
for DSM-IV (SCID) (28) or Schedule for Affective Disorders and Schizophrenia (SADS) 
(29). These diagnostic questionnaires produce DSM-IV diagnoses. If parents were not 
evaluated, their phenotype was defined as unknown. Dizygotic and monozygotic twins were 
excluded. All subjects were of Caucasian origin. Seventy families were recruited as part of the 
European Collaborative Study of Early-Onset BPAD. Among these 70 families, 27 came from 
Germany (10 of these German families were included in a previous genome scan (30)), 16 
from Ireland, 11 from France, 6 from Scotland, 6 from Switzerland and 4 from England . The 
protocol was approved by an ethics committee in each participating country and all subjects 
signed informed consent forms. 
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Disease Classification 
All probands were diagnosed with early-onset type I BPAD and were thus considered to be 
affected. For the sib-pair analysis, we defined two phenotypes. For the “broad phenotype”, 
siblings were considered as affected if they had BPAD type I or II or bipolar-type schizo-
affective disorder, regardless of AAO, or if they had a major depressive episode (single or 
recurrent) with an AAO of 21 years or below. For the “narrow phenotype”, siblings were 
considered as affected if they suffered from BPAD type I with an AAO of 21 years or less, as 
for probands. The sample consisted of 87 sib-pairs according to the broad phenotype. Among 
them, 29 sib-pairs met the criteria for the narrow phenotype definition.  
 
Genotyping 
Genomic DNA was isolated from peripheral blood leukocytes by the phenol/chloroform 
method. The genome-screen included 384 highly polymorphic microsatellite markers (Linkage 
Marker Set MD 10 (Applied Biosystems, Foster City, CA, USA)) and was performed at the 
Centre National de Génotypage (CNG - France). The average spacing between markers was 9.2 
cM, with the largest gaps between D6S1610-D6S257 (23.8 cM) and D21S1911-D21S1914 
(22.5 cM). The average heterozygosity was 75%. Automatic genotyping was performed by 
applying the following processes implemented in the Genetic Profiler software (version 1.1) to 
the raw MegaBACE data: trace processing, fragment sizing, allele calling and assigning 
genotype quality scores. A quality score (QS) was assigned to each genotype. This QS is based 
on the quality of the amplification, the morphology of the marker, the presence or the absence 
of spurious peaks and the allele favoritism (case of the heterozygous samples only) but also on 
the deviation of the observed value from the median value for the allele, weighted by the 
standard deviation of the distribution over all observations. Before statistical analysis, rigorous 
genotype quality assurance was performed to ensure accurate binning of alleles. The 
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consistency of the data with mendelian inheritance and the lack of recombination between loci 
were evaluated using Pedcheck (31) and other purpose-written programs. Potentially incorrect 
genotypes were re-examined and retested if necessary. The mean success rate of genotyping is 
95 per cent. Allele frequencies were determined using the FBAT software (32) and were 
compared to those available in databases (http://www.cephb.fr; http://www.genethon.fr; 
http://www.chg.duke.edu). We checked that the marker maps used in our analysis were 
consistent with published maps (http://research.marshfieldclinic.org). Marker locations 
(distance from p-ter) were extracted from the Marshfield database 
(http://research.marshfieldclinic.org). Cytogenetic location was extracted from the Human 
Genome Browser on the Sanger Institute website (http://www.ensembl.org/Homo_sapiens). 
DNA was available for all sib-pairs and for 76.9 % of parents. 
 
Additional linkage analyses with increased marker density 
After genome-wide search analysis, we performed additional linkage analyses with increased 
marker density using 28 additional markers. Eleven of them were located in regions 
suggestive for linkage at p=0.01 and having an average information contents lower than 75% 
(3p14, 10q23, 16q23 and 20p12). This led to an average spacing between markers around 4 
cM for these regions. Seventeen markers were spread in other regions with low informativity. 
 
Non Parametric Linkage analysis 
The traditional LOD-score method is not directly applicable when the disease model is unknown, 
as is the case for many common heritable disorders. We thus performed linkage analyses using 
model-free methods that do not require specification of the underlying genetic model for the trait 
being investigated. Non parametric bi-point and multipoint linkage analyses were performed 
using the NPL (Non Parametric Lodscore) statistic of the GENEHUNTER 2.1 program (33). The 
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strength of the linkage was expressed as NPL score and p-value. The NPL score was defined as 
the sum of NPL over the n pedigrees. For the ith pedigree, the NPL score was defined as 
NPL(i)=[S(v)-m]/s, where S(v) is the number of pairs of alleles identical by descent for the two 
sibs given the inheritance vector v, and m and s are respectively the mean and the standard 
deviation of S under the uniform distribution over the possible inheritance vectors. If allele 
sharing identical by descent in sib-pairs could not be directly determined (e.g. when DNA from 
one or both parents was missing), parental haplotypes were estimated based on the haplotypes of 
their offsprings. Under the hypothesis of no linkage, when there is complete parental 
information, the p-value can be calculated from the distribution of all the possible inheritance 
vectors. When parental haplotypes are estimated, we can either use an estimation of the complete 
information case or use the property that the NPL score tends towards a standard normal variable 
with a mean of 0 and a variance of 1. As few families in our sample included three affected sibs, 
all possible pairs were considered without using any weighting procedure. Indeed, when the 
number of sib-ships of size 3 or more is moderate, forming all possible pairs only slightly 
increases type I errors, whereas frequently used weighting procedures decrease the efficiency of 
the tests (34). 
 
Test for parent-of-origin effect 
Paternal and maternal inheritances were investigated using the ASPEX program (35). This 
method reports identity-by-descent information for all affected sib-pairs in nuclear families. At a 
given locus, for each parent, the program compares the corresponding alleles for each member of 
an affected sib-pair. If both alleles can uniquely be identified, the pair is scored as either 
identical or non-identical by descent from that parent, at that position. If the match is ambiguous, 
the position is scored as being uninformative. If data from additional siblings are available, they 
are used to reconstruct missing parents. To test for a parent-of-origin effect, we used a classical 
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chi-square test to compare maternal and paternal allele sharing. To correct for multi-testing, we 
applied the classical Bonferroni correction. 
 
Simulation study 
As we conducted multiple analyses for multiple markers, we carried out a simulation study to 
estimate the genome-wide empirical p values. Given the small number of families, it is 
preferential to use simulations, rather than asymptotic theory (Holmans 2001). Marker allele 
frequencies and map distances were kept as in the original sample and genotypes were 
dropped through the 70 families, with the SIMULATE program (36). This program was 
modified to keep the original founder’s genotypes, under the hypothesis of no linkage 
between the disease and the markers. Our aim was to obtain the same information for 
replicates and the original set: the same parental genotypes, the same map distances, missing 
individuals for each marker and phenotypes for each individual. To estimate the genome-wide 
p values, we simulated 10.000 replicates for the 22 autosomes. The phenotypes were not 
simulated, and each individual was attributed his or her real set of phenotypes. These 
replicates were analyzed by genome-wide multipoint analyses. For each replicate i, the 
maximum NPL score (NPLMi) was recorded. For example, the genome-wide p value for a 
NPL of 3.51 was determined by the number of times NPLMi exceeded 3.51 divided by the 
number of replicates. This gave us the genome-wide p value accounting for multiple testing at 
all positions of the genome. We were also able to calculate the number of occurrences of a 
given NPL in each replicate NbT. This process was implemented in the FDB linkage and 
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Description of the sample 
We recruited 70 nuclear families ascertained through an early onset BPAD, including 87 sib-
pairs according to the broad phenotype definition. Among them, 29 sib-pairs were considered 
as affected using the narrow phenotype definition. For the broad phenotype, mean AAO was 
17.2 ± 2.4 years (range 11-21 years) for probands and 22.0 ± 6.8 years (range 9-46 years) for 
siblings. The sex (male/female) ratio was 0.66 for probands and 0.76 for siblings. The siblings 
were diagnosed with: BPAD type I (69.6%; N=55), BPAD type II (13.9%; N=11), bipolar-type 
schizo-affective disorder (10.1%; N=8) and major depressive episode (single or recurrent) 
(6.3%; N=5). For the narrow phenotype, mean AAO was 17.4 ± 2.5 years (range 12-21 years) 
for probands and 17.5 ± 2.9 years (range 9-21) for siblings. The sex ratio was 0.80 for probands 
and 0.87 for siblings.  
 
Non parametric linkage analysis 
The results of the non parametric bi-point linkage analysis are presented in table 1. When all 
p-values were non-significant over a region of more than 20 cM between two markers in 
favor of linkage (i.e. with a p<0.05), markers were assumed to detect different regions of 
linkage. Four regions had a p-value < 0.01: the 3p14.1-14.3 region linked to the broad 
(p=0.002) and narrow (p=0.01) phenotypes respectively; the 10q23.33-q24.31 and 20p12.2 
regions linked to the broad phenotype only (p=0.01 and p=0.002 respectively) and the 
16q23.1 region linked to the narrow phenotype only (p=0.004). The 2p21-p23.2 and the 
17q11.2-q22 regions had a p-value < 0.05 for adjacent markers (p=0.02 for the broad 
phenotype in 2p and p=0.03 for the narrow phenotype in 17q).  None of the 13 chromosome 
X markers was suggestive for linkage. 
Non parametric multipoint linkage analysis plots are described in figure 1 for both 
phenotypes. Multipoint NPL value are reported in table 2 for each chromosomal regions 
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identified in bi-point analysis. Most of the 13 regions reached NPL values at the maximum 
multipoint test statistic that were higher than those obtained by single point analysis. The only 
exceptions were found at chromosomes 7q21.3, 10p13 and 16q23.1, for which a lower or 
equal significance level in multipoint analysis was obtained comparing to single-point 
analysis. Non parametric multipoint linkage analysis of these regions revealed significant 
linkage (p<0.01) for at least one phenotype in the following regions: 2p21 (NPL=2.8, 
p=0.003), 2q14.3 (NPL=2.24; p=0.01), 7q36 (NPL=2.43; p=0.007), 10q23 (NPL=2.45; 
p=0.007) and 20p12 (NPL=2.25; p=0.01) only for the broad phenotype, 3p14 for both the 
narrow (NPL=1.65; p=0.004) and broad phenotypes (NPL=3.51 p=0.0002), and 5q33 
(NPL=1,4; p=0.01) and 16q23 (NPL=1.64; p=0.005) only for the narrow phenotype.  
 
Additional linkage analyses with increased marker density 
Among the most significant regions (p<0.01 in multipoint analyses) and when information 
contents was lower than 75%, eleven additional markers were genotyped (in regions 3p14, 
10q23, 16q23 and 20p12). For these regions, the location of the peak of linkage remained 
unchanged and the information content improved by about 10% in each region. In 
chromosome 3 region, the NPL score increased from 3.51 to 3.83 (broad phenotype, 
p=0.00005) and from 1.65 to 1.70 (narrow phenotype, p=0.003). In chromosome 10, the NPL 
score decreased from 2.45 to 2.25 (broad phenotype, p=0.01). In chromosome 16, the NPL 
score decreased from 1.64 to 1.33 (narrow phenotype, p=0.02). In chromosome 20, the NPL 
score increased from 2.25 to 2.5 (broad phenotype, p=0.006). We have also genotyped 17 
markers spread in other regions with low informativity. Analyses of additional markers in 
these regions did not change the results of the multipoint linkage analysis (data not shown). 
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Simulation study 
For the broad phenotype, a NPL of 3.51 corresponded to a genome-wide p-value of 0.015 
[0.01-0.02] on the basis of simulations. According to simulations, a NPL score equal and 
higher than 3.23 would be needed to achieve empirical genome-wide significance at the 0.05 
level in our data. Therefore, only the 3p14 region was still significant according to the   
genome-wide p-value. 
 
Paternal and maternal contributions to linkage detection 
Parent-of-origin effect was investigated in the eight regions linked to at least one phenotype 
with a p-value lower than 0.01 (see Table 3). An excess of maternal sharing compared to 
paternal sharing was suggested for 3p14 for the narrow phenotype (ORmaternal=9.3 [1.6-54.8]; 
p=0.008) and an excess of paternal sharing was suggested for 10q23 with both phenotypes 
(ORpaternal=5.0 [1.0-24.9]; p=0.03 for the narrow phenotype and ORpaternal=2.3 [1.0-5.5]; p=0.05 
for the broad one). When Bonferroni’s correction for multi-testing was applied, no parent-of-




The aim of our study was to search for genes implicated in bipolar affective disorder. We 
hypothesized that ascertaining families through an early onset bipolar I patient led to select an 
homogeneous sample of patients. As the traditional LOD score method cannot be applied 
directly when the disease model is unknown, we used model-free methods to search for 
chromosome regions linked with BPAD in a sample of 70 European families ascertained 
through an early-onset BPAD type I proband. Non parametric multi-point analysis identified 
eight regions of linkage with p-values <0.01 (2p21, 2q14.3, 3p14, 5q33, 7q36, 10q23, 16q23, 
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20p12). The genome-wide p-value at 3p14 was 0.01, estimated by our simulation study of 
10.000 replicates. Interestingly, an excess of maternal sharing for the 3p14 region and an 
excess of paternal sharing for 10q23 were suggested but these results did not remain 
significant after Bonferroni’s correction for multi-testing. 
In this multicentric study, diagnoses for affective disorders were generated using the 
following instruments : DIGS, CIDI, SCID or SADS. All these questionnaires generated 
DSM-IV criteria based diagnoses. Differences in sensitivity and specificity of these 
instruments may have introduced some clinical heterogeneity. However, inclusion criteria 
were strictly based on DSM-IV affective disorders definitions and all centers used the same 
stringent definition for age at onset. Using these strict inclusion criteria may have restricted 
the heterogeneity inherent in our multicentric study design.  
As expected, there is a high concordance between probands and siblings diagnoses as 70% of 
siblings (N=55) were diagnosed with BPAD type I, 14% with BPAD type II (N=11), 10% 
with schizo-affective disorder bipolar type (N=8) and 6% of major depressive episode (single 
or recurrent; N=5). We determined a strict threshold to define age at onset for proband 
inclusion criteria (equal or lower than 21 years). Using such a criteria led us to analyse a small 
sample of sib-pairs for the narrow phenotype. With a less stringent AAO criteria (equal or 
lower than 25 years), 74 of 87 sib-pairs (85%) would have been concordant for age at onset, 
whatever there primary affective diagnoses were.  
Regions 2p21, 3p14, 5q33 and 20p12 appeared to be linked to both phenotypes, whereas 
2p14.3, 7q36 and 10q23 showed linkage only to the broad one. These results might be 
interpreted as a gain of power due to sample size (29 sib-pairs for the narrow phenotype 
versus 87 for the broad one). 
Examination of (i) the number of studies revealing positive linkage, (ii) the degree of overlap 
between the detected regions and (iii) similarities in phenotypic definition may shed some 
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light on these results. Seven of these regions have previously been reported to be linked to 
BPAD. Regions 3p14, 7q36, 10q23 and 20p12 are particularly interesting as they were 
detected in our sample and in at least two of the previously published scans in BPAD using a 
significance threshold of p<0.01 (see table 4). Chromosomal regions 2p21 (38, 39), 3p14 (40-
42), 7q36 (43, 44) and 20p12 (45, 46) were previously identified in three independent studies, 
reinforcing the hypothesis of linkage. Some of these regions (2p21, 7q36, 20p12) were also 
detected in a previous genome scan (30). However, since some families were analyzed in this 
paper and in our study, our results cannot be considered to be an independent replication. The 
16q24 region, which was significant only with our narrow definition, has not been described 
in any BPAD genome scan. This result could be a false positive due to multi-testing. Our 
approach, using both BPAD type I and AAO as inclusion criteria for probands, allowed us to 
select only seven regions among numerous regions suggested by published genome-wide 
searches of BPAD and to suggest the implication of the 3p14 region. 
We investigated if any candidate genes reported as associated with early-onset BPAD could 
be located near regions of linkage. Our study showed a bi-point NPL of 1.2 (p=0.03) for the 
narrow phenotype at marker D17S798, which is about 3 cM from the serotonin transporter 
gene (SLC6A4). We did not find any significant linkage in regions containing other candidate 
genes (i.e. glycogen synthase kinase 3-beta and dopamine receptor D3 located in 3q13 and 
apoliproprotein E located in 19q13). These genes might have only a weak effect on BPAD or 
this result may be due to the peculiarities of our sample, such as mode of ascertainment or 
false positive results (13, 14, 16).  
As there is large confidence interval for linkage in these regions (i.e 38 cM for 2p21, 25 cM 
for 2q14.3, 18 cM for 3p14, 33 cM for 5q33, 18 cM for 7q36, 17 cM for 10q23 and 12 cM for 
the 20p12 regions), we are currently undergoing the fine mapping of the regions of interest. 
Our preliminary findings require confirmation in independent panels of families. 
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Table 1:  
Non parametric bi-point linkage analysis - Regions detected with a p value ≤0.05 
 
Cytogenetic Marker Dist. from IC* Narrow phenotype Broad phenotype
location name p-ter (cM)  NPL p-value NPL p-value
2p23.2 D2S165 47.43 0.70 0.59 0.17 1.67 0.05 
2p22.3 D2S367 54.96 0.74 0.9 0.08 1.7 0.04 
2p21 D2S2259 64.29 0.64 0.69 0.14 1.61 0.05 
2p21 D2S391 70.31 0.58 0.42 0.25 1.94 0.02 
#        
2q14.3 D2S347 131.51 0.56 0.57 0.18 1.65 0.05 
#        
3p14.2 D3S1300 80.32 0.68 1.47 0.01 2.88 0.002 
3p14.1 D3S1285 91.18 0.56 0.46 0.23 1.96 0.02 
#        
4q13.3 D4S392 78.97 0.64 0.70 0.14 1.68 0.04 
#        
5q32 D5S436 147.49 0.68 1.10 0.04 0.84 0.20 
#        
7q21.3 D7S657 104.86 0.65 0.62 0.16 1.64 0.05 
#        
7q36 D7S798 168.98 0.67 0.12 0.43 1.83 0.03 
#        
10p13 D10S1653 40.36 0.7 1.07 0.04 0.51 0.30 
#        
10q23.33 D10S185 116.34 0.66 0.50 0.22 2.25 0.01 
10q24.31 D10S192 124.27 0.66 -0.06 0.54 1.88 0.03 
#        
16p13.2 D16S404 18.07 0.69 1.26 0.02 1.14 0.12 
#        
16q23.1 D16S516 100.39 0.6 1.64 0.004 1.36 0.08 
#        
17q11.2 D17S798 53.41 0.58 1.17 0.03 0.33 0.37 
17q21.32 D17S1868 64.16 0.63 0.97 0.06 0.87 0.19 
17q22 D17S787 74.99 0.63 1.01 0.05 0.9 0.18 
#        
20p12.2 D20S186 32.3 0.65 0.3 0.32 2.93 0.002 
 
# indicates two different regions (markers were assumed to detect different regions of linkage 
if all p-values were non-significant over a region of >20 cM between two markers with 
significant linkage). 
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Table 2:  
Non parametric multipoint linkage analysis 
 







 from p-ter  NPL p-value NPL p-value 
D2S2259-D2S391 64.29 0.83 1.03 0.05 2.78 0.003 
       
D2S347 131.51 0.74 0.48 ns 2.24 0.01 
       
D3S1300 80.32 0.83 1.65 0.004 3.51 0.0002 
       
D4S392 78.97 0.78 0.81 ns 1.73 0.04 
       
D5S410 156.47 0.80 1.37 0.01 1.51 0.06 
       
D7S657 104.86 0.81 0.48 ns 1.49 0.07 
       
D7S798 168.98 0.82 0.19 ns 2.43 0.007 
       
D10S1653 40.36 0.85 1.07 0.04 0.43 ns 
       
D10S185 116.34 0.80 0.20 ns 2.45 0.007 
       
D16S404 18.07 0.86 0.99 ns 1.70 0.04 
       
D16S516 100.39 0.76 1.64 0.005 1.07 0.14 
       
D17S944 82.56 0.79 1.28 0.02 0.39 ns 
       
D20S186 32.30 0.81 0.05 ns 2.25 0.01 
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Table 3: Test for parent-of-origin effect 
 
 Narrow phenotype Broad phenotype 








Locus %ibd χ² %ibd χ² 
Test for parental 
contribution 
χ² (p-value) 
%ibd χ² %ibd χ² 
Test for parental 
contribution 
χ² (p-value) 
           
D2S2259 53.3 0.07 57.9 0.47 0.07 (ns) 65.1 3.93 57.1 1.00 0.6 (ns) 
D2S391 57.1 0.29 53.3 0.07 0.04 (ns) 71.8 7.41 57.1 0.86 1.9 (ns) 
           
D2S347 77.8 2.78 55.6 0.11 1.0 (ns) 69.7 5.12 60.6 1.48 0.6 (ns) 
           
D3S1300 41.2 0.53 86.7 8.07 7.0 (0.008) 52.1 0.08 70.2 7.68 3.3 (0.07) 
           
D5S410 56.2 0.25 72.2 3.56 0.9 (ns) 50.0 0.00 53.1 0.18 0.01 (ns) 
           
D7S798 44.4 0.22 47.8 0.04 0.05 (ns) 59.6 1.72 52.6 0.16 0.5 (ns) 
           
D10S185 81.2 6.25 46.7 0.07 4.0 (0.04) 70.8 8.33 51.1 0.02 3.8 (0.05) 
           
D16S516 73.3 3.27 80.0 5.40 0.2 (ns) 61.8 1.88 60.0 1.40 0.02 (ns) 
           
D20S186 61.5 0.69 50.0 0.00 0.4 (ns) 69.6 7.04 71.1 8.02 0.03 (ns) 
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Table 4:  
Regions detected in published genome screens and replicated in the European families 
for BPAD phenotypes (p<0.01) 
 
Early onset BPAD 
Peak of linkage 
Previous genome wide searches 
of BPAD Region Distance from p-ter Marschfield (cM) 
Phenotype (p-value) Authors (Year) 
2p22-p25 28-55  Detera-Wadleigh (1999), Cichon 
(2001) 
2p21 64 Broad (p=0.003)  
2p14 87  Liu (2003) 
#    
2q14 131 Broad (p=0.01)  
2q21 142-147  Cichon (2001); Ewald (2003) (47) 
#      
3p14 62-79  Fallin (2004), Kelsoe (2001) 
3p14 80 Narrow (p=0.004) 
Broad (p=0.0002) 
  
3p13-p14 90-103  Mc Innes (1996), Kelsoe (2001), 
Cichon (2001), Radhakrishna 
(2001) 
#      
5q33 156 Narrow (p=0.01)   
5q33 160  Edenberg (1997) (48) 
5q35 184  Detera-Wadleigh (1999) 
#      
7q34-q36 147-161  Cichon (2001), Detera-Wadleigh 
(1997), Curtis (2003) 
7q36 168 Broad (p=0.007)   
#      
10q23 116 Broad (p= 0.007)   
10q24-q25 124-134  Cichon (2001), Kelsoe (2001) 
#      
16q24 100 Narrow (p=0.005)   
16q24 129  Mc Innes (1996) 
#      
20p12 25  Morissette (1999) 
20p12 32 Broad (p=0.01)   
20p12 33-39  Radhakrishna (2001), Morissette 
(1999), Cichon (2001) 
 
# Markers were assumed to detect different regions of linkage if all p-values were non-
significant over a region of > 20 cM between two markers with significant linkage. 
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